Frontiers in Immunology Releases New IncellDx Study Data Supporting Model to Understand Long Cause of COVID
SAN CARLOS, Calif .– (COMMERCIAL THREAD) – IncellDx, a precision medicine company, the newspaper announced today Frontiers in immunology published a study detailing a framework for understanding the potential mechanism and potential treatment of the post-acute sequelae of COVID-19 (PASC), also known as long-range COVID or long-range COVID.
“Recent analysis confirms that long COVID is impacting a significant number of people, and its prevalence could increase due to the emergence of the Omicron variant,” said Bruce Patterson, MD, CEO of InsellDx. “We know this is a very widespread and growing problem. What doctors lack is an understanding of the underlying cause of long COVID and a way to objectively diagnose and treat it. We believe this study provides additional evidence for a meaningful way forward for diagnosis and treatment. ”
In the study, Persistence of SARS CoV-2 S1 protein in CD16 + monocytes in post-acute sequelae of COVID-19 (PASC) for up to 15 months after infection, patients with previous COVID infection and persistent symptoms were found to have a distinct immunologic profile characterized by differentiated proportions of monocyte subsets. In the study, the presence of the SARS-CoV-2 S1 protein was investigated in 46 people. T-cell, B-cell and monocytic subsets have been analyzed both in patients with severe COVID-19 and in patients with post-acute COVID-19 sequelae (PASC). The levels of intermediate (CD14 +, CD16 +) and non-classical (CD14Lo, CD16 +) monocytes were significantly increased compared to healthy controls. None of the monocyte subsets were elevated in severe COVID-19 cases. In addition, the S1 subunit of the SARS-CoV-2 protein was present in unclassical monocytes in patients suspected of having PASC up to 16 months after initial infection. Monocytes, a type of white blood cell, are involved in adaptive immunity and play a key role in attacking viruses and other pathogens.
A previous article from IncellDx in Frontiers in immunology proposed the first model for diagnosing, indexing and tracking long COVIDs. In this study, Immune system-based prediction of severity and chronicity of COVID-19 decoded using machine learning, 224 individuals, including healthy controls and patients spanning the COVID-19 disease continuum, were assessed using machine learning for severity and chronic symptoms after initial infection. CCL5 / RANTES, IL-2, IL-4, CCL3, IL-6, IL-10, IFN-γ and VEGF were all significantly elevated in long-term COVID patients compared to healthy controls (P data was analyzed to generate objective disease scores for PASC patients and severe COVID patients.
“The S1 protein is believed to cause inflammation, particularly vascular inflammation, which contributes to the hallmark symptoms of long COVID,” Patterson continued. “At IncellDx, we would like to congratulate all the groups who contributed to this critical publication showing the persistence of S1 protein in white blood cells months and now almost 2 years after SARS-CoV-2 infection in patients. suffering from long COVID or PASC. Critically, the data also shows the persistence of COVID RNA in these cells, but whole genome sequencing has revealed that they are RNA fragments unable to replicate. We are also excited to deploy Quantum Si’s single-molecule protein sequencing platform so that we can identify Omicron long-haul routes and determine whether mutated S1 proteins contribute to a different disease course in adults and patients. children in new variations such as Delta and Omicron.
Purvi Parikh, MD, an allergy and immunology specialist at NYU Langone Medical Center and co-founder of the Chronic COVID Treatment Center, said, “We knew the persistent inflammation was probably the cause of PASC and now with over evidence about the nature of inflammation, we can use targeted therapies to hopefully relieve these patients of this relentless disease. ”
IncellDx is a precision medicine company providing novel diagnostics and prognosis to better understand and treat infectious disease and cancer. The company’s innovative technology platform enables cell classification and unique cell analysis of proteomic and genomic biomarkers. The company launched the Chronic COVID Treatment Center to apply precision medicine approaches to assess, characterize, and more effectively treat chronic COVID.